Cardiovascular MRI best modality for evaluating suspected cardiac tumors: Study

"This was important to study because, until now, there was no great data supporting current clinical practice of using CMR to investigate these patients," said lead author Chetan Shenoy, MBBS, MS, an associate professor in the Department of Medicine's Cardiovascular Division at the U of M Medical School. "For example, if CMR shows no cardiac tumor or mass, we do not do any further testing — we do not know if this is the right approach and how well CMR serves this purpose. In this study, we wanted to validate that clinical practice."

This multicenter study, published in the European Heart Journal, involved 903 patients from four institutions. Some of the key findings of the study are that:

• CMR diagnosis was accurate in 98.4% of patients in the study;

• CMR diagnosis is a powerful, independent predictor of death; and,

• This prognostic value is incremental to clinical factors.

"These data provide the first large-scale validation of the clinical practice of using CMR to exclude a cardiac tumor and to diagnose the type of tumor," said Shenoy, who is also a cardiologist with M Health Fairview. "By demonstrating high accuracy and long-term prognostic value, our results confirm that CMR can be used as a 'one-stop-shop' for this clinical indication. We anticipate our findings will shape future guidelines, appropriateness documents and health policies on this topic."

Co-authors on the paper include John D. Grizzard and Marianna Zagurovskaya from Virginia Commonwealth University Medical Center; Dipan J. Shah, Mahwash Kassi and Michael J. Reardon from Houston Methodist Hospital; and Han W. Kim, Michele A. Parker and Raymond J. Kim from Duke University Medical Center.